Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioCryst Pharmaceuticals, Inc.    BCRX

BIOCRYST PHARMACEUTICALS, INC. (BCRX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

BioCryst Pharmaceuticals : terminates merger agreement with Idera

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 10:43am CEST

US-based BioCryst Pharmaceuticals has terminated the merger agreement with Idera Pharmaceuticals after its stockholders voted against the proposed deal.

However, most of the Idera stockholders supported and voted in favour of the merger.

Under the terms of the original merger agreement signed in January this year, the termination will trigger a refund of $6m from BioCryst to Idera to cover transaction-related expenses.

BioCryst Pharmaceuticals board chairman Robert Ingram said: We are focused on serving the interests of all stockholders in their desire for BioCryst to pursue a standalone strategy and continue our path to treating patients with rare and serious diseases.

The board and management are steadfast in our commitment to capitalise on the opportunities in BioCyrsts current portfolio and advance the promising candidates in the Companys pipeline to generate stockholder value.

BioCryst and Idera planned to combine their respective businesses for the development and commercialisation of drugs to treat patients with rare diseases.

The combined entity would have possessed a pipeline of two Phase II candidates and Phase III candidates each. They also planned to leverage each others drug discovery capabilities and clinical expertise to expand the development efforts.

Idera Pharmaceuticals CEO Vincent Milano said: The board and shareholders of Idera overwhelmingly supported the proposed merger with BioCryst based on the strategic rationale, operating synergies and opportunity to create a stronger and more diversified rare-disease, focused organisation.

Our tilsotolimod would have been one of the two centrepiece product opportunities of the combined company.

As an independent company, Idera now plans to primarily continue developing tilsotolimod for anti-PD-1 refractory melanoma and investigate its application in other solid tumours.

Milano added that the company will explore any opportunities to further improve shareholder value and grow through business development.

(c) 2003-2018 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
BIOCRYST PHARMACEUTICALS, INC. 1.78% 7.45 Delayed Quote.51.73%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOCRYST PHARMACEUTICALS,
09/25BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcar..
GL
09/19BIOCRYST PHARMACEUTICALS : Receives Additional $3.5 Million to Fund Clinical Tri..
AQ
09/17BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesi..
GL
09/10BIOCRYST PHARMACEUTICALS : CDC Awards BioCryst $35 Million RAPIVAB Contract for ..
AQ
09/07BIOCRYST PHARMACEUTICALS : CDC Awards BioCryst $35 Million RAPIVAB Contract for ..
AQ
09/06BIOCRYST PHARMACEUTICALS : Reports Positive Results across Multiple Endpoints in..
AQ
09/06BIOCRYST PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other..
AQ
09/06CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stoc..
GL
09/05BIOCRYST PHARMACEUTICALS : Reports Positive Results Across Multiple Endpoints in..
AQ
09/04BIOCRYST PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form..
AQ
More news
News from SeekingAlpha
09/07After Hours Gainers / Losers (09/07/2018) 
09/04BioCryst's BCX7353 shows positive action in mid-stage HAE study; shares up 5%.. 
08/23FDA OKs Shire's Takhzyro for HAE 
08/20WEEK 34 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
08/08YOUR DAILY PHARMA SCOOP : Foundation Promising, Paratek Moves Up, Ovid Down 
Financials ($)
Sales 2018 26,8 M
EBIT 2018 -79,0 M
Net income 2018 -91,7 M
Finance 2018 55,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 27,9x
EV / Sales 2019 41,5x
Capitalization 805 M
Chart BIOCRYST PHARMACEUTICALS, INC.
Duration : Period :
BioCryst Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCRYST PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 10,3 $
Spread / Average Target 38%
EPS Revisions
Managers
NameTitle
Jon P. Stonehouse President, Chief Executive Officer & Director
Robert Alexander Ingram Chairman
Robert Bennett Vice President-Investor Relations & Operations
Thomas R. Staab CFO, Treasurer, Principal Accounting Officer & SVP
William P. Sheridan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOCRYST PHARMACEUTICALS, INC.51.73%805
GILEAD SCIENCES4.68%98 029
VERTEX PHARMACEUTICALS21.88%46 555
REGENERON PHARMACEUTICALS3.75%41 417
NEUROCRINE BIOSCIENCES, INC.58.06%10 951
SAREPTA THERAPEUTICS INC175.16%10 172